OIG will investigate off-label claims

Share this article:
The HHS Office of the Inspector General (OIG) says in its FY 2008 work plan that it will "assess FDA's oversight and review of allowable off-label drug promotion and enforcement." Lately, the federal government has won numerous pharmaceutical company settlements under the False Claims Act that are centered on off-label drug uses.

The work plan also says CDER's generic drug approval process will come under the microscope in 2008, particularly the reasons for the growing backlog of submissions.

“We will review FDA's timeframes for reviewing original generic drug applications and identify factors that affect the timely review of these applications,” it says.

Despite regulations mandating review actions within 180 days after submission, over 1,000 generic drug applications are currently pending, with one-third of these exceeding the statutory time limit.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric